Back to Medicines

Darunavir: A Protease Inhibitor and Its Booster

Darunavir: A Protease Inhibitor and Its Booster
Prescription Medicines Editorial 4 January 2026

Darunavir is a protease inhibitor. HIV protease cuts newly made viral proteins into working pieces, and blocking it produces virus particles that cannot mature or infect new cells. Darunavir's defining characteristic is a high barrier to resistance - it takes multiple accumulated mutations to compromise it, rather than one. That makes it particularly valuable for people whose adherence is difficult, and for those who already have resistance to other drugs.

Follow the plan your HIV team gave you. This guide contains no doses.

It always comes with a booster

Darunavir is cleared quickly by the liver enzyme CYP3A4, so on its own it does not reach useful levels. It is always given with a booster - either ritonavir or cobicistat - that blocks that enzyme.

The booster contributes nothing to treating HIV. Its entire function is to slow darunavir's breakdown.

It also brings a very large interaction profile with it, and that profile belongs to the booster rather than to darunavir. See ritonavir and cobicistat - the interaction sections there apply to you even though the booster is the smaller part of your tablet.

Take it with food

Food substantially increases absorption. Taken on an empty stomach, levels fall enough to matter.

Take it with a meal or substantial snack at the same time each day.

Why the resistance barrier matters

Most HIV drugs lose effectiveness once a single key mutation appears. Darunavir binds in a way that tolerates individual mutations, so several must accumulate before it fails.

Practically, that means it is more forgiving of imperfect adherence - not that adherence stops mattering, but that the consequences of an occasional missed dose are less likely to be permanent.

It is therefore often chosen for people starting treatment in difficult circumstances, for those with a history of treatment interruption, and for salvage regimens after other drugs have failed.

Resistance, once it does develop, is still permanent - see dolutegravir for why.

Once daily or twice daily

Boosted darunavir is taken once daily for most people starting treatment, and twice daily where there is significant existing resistance or in later pregnancy, when levels fall.

The two regimens are not interchangeable, and switching between them is a prescribing decision based on your resistance history. If your instructions change, check what you should be taking and when the change starts.

The sulfonamide rash

Darunavir contains a sulfonamide group, and rash is one of its commoner side effects - usually mild, usually in the first weeks, and usually settling without stopping.

Serious skin reactions including Stevens-Johnson syndrome have been reported rarely.

Stop and seek urgent medical help for a widespread rash with fever, blistering, peeling skin, or sores in the mouth, eyes or genitals. See rashes from medicines.

Tell your team about any sulfonamide allergy, and be specific about what happened - see allergy or side effect.

Other side effects

Diarrhoea, nausea, abdominal pain and headache are the common ones, generally worse early.

Raised cholesterol and triglycerides occur with protease inhibitors as a class, and lipids are monitored. Statins are affected by the booster, so which one you take and at what dose is a deliberate choice - see statins and muscle pain.

Raised blood glucose and changes in fat distribution are recognised with longer-term use.

Report jaundice, dark urine or persistent abdominal pain - liver reactions occur, particularly in people with hepatitis B or C co-infection. See medicines and your liver.

Monitoring

Viral load and CD4 count regularly, plus liver and kidney function, lipids and glucose.

If you take the cobicistat-boosted version, expect a small early rise in creatinine that reflects a transport effect rather than kidney damage - worth knowing so it does not cause alarm when a GP sees it out of context.

See monitoring long-term medicines.

In pregnancy

Boosted darunavir is used in pregnancy and has a reasonable safety record, though levels can fall in the later stages, which is why twice-daily dosing is sometimes preferred then.

Effective HIV treatment during pregnancy reduces the risk of passing the virus to the baby to well under one per cent. Do not stop treatment if you become pregnant - contact your HIV team, who will review rather than interrupt it.

The practical rule

Every new medicine needs checking - every time. That includes prescriptions from dentists, urgent care and online services, and anything bought over the counter, herbal or recreational.

Inhaled and nasal steroids are the interaction people least expect, because the booster can turn an ordinary inhaler into a cause of Cushing's syndrome. See steroid inhaler safety.

St John's wort must be avoided - see supplements that interfere with your medicines.

Free HIV interaction checkers exist online, and your specialist pharmacist will check for you before you take the first dose.

Cyproheptadine: Appetite, Allergy and Migraine covers a related point, and the Medicines section has the rest of these guides.